EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Sexual Dimorphism in Levodopa‐Induced Dyskinesia Following Parkinson's Disease: Uncharted Territory

Lily M Bentall iD, Louise C Parr-Brownlie iD

European Journal of Neuroscience · 2025

DOI: 10.1111/ejn.70144 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Neuroscience, 2025. Verfasst von Lily M Bentall und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy, University of Otago, Dunedin, New Zealand. Hauptthemen laut MEDLINE: Levodopa, Parkinson Disease, Sex Characteristics, Dyskinesia, Drug-Induced. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 308 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Neurological Foundation of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sexual dimorphism is well‐documented in Parkinson's disease (PD); however, when it comes to levodopa‐induced dyskinesia (LID), epidemiological and clinical findings are scarce. This is an oversight because recent studies show significant correlations between LID risk and female sex. Estrogen strongly impacts neuronal function, affecting cognitive tasks such as movement, object recognition, and reward. In movement pathways, estrogen increases dopamine synthesis, transmission, and regulation, resulting in neuroprotection for PD in women. However, following menopause, PD prevalence, symptom severity, and LID risk increase for women. Consequently, early to mid‐life estrogen state is neuroprotective, but later in life becomes a risk factor for PD and LID. This review explores estrogen's action in the brain, specifically within the dopamine system. Sexual dimorphism is described for the prevalence and onset of PD and LID. We examine the cellular basis of estrogen's role in sexual dimorphism and integrate these ideas to hypothesize why the risk for LID is higher for women, than men, with PD. Lastly, this review proposes that women with PD need their symptoms to be considered and managed differently to males. Treatment of women with PD should be based on their menopausal stage, as estrogen may be masking, exacerbating, or complicating symptoms. Importantly, we present these concepts to stimulate discussion among clinical and bench scientists so that key experiments can be conducted to examine the mechanisms underlying LID, so they can be prevented to improve the quality of life for women and men living with PD in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LevodopaParkinson DiseaseSex CharacteristicsDyskinesia, Drug-InducedAntiparkinson AgentsHumansFemaleMaleEstrogensAnimals

Stichwörter der Autor:innen

Parkinsonbasal gangliaestrogenlevodopa‐induced dyskinesiamenopausesexual dimorphismstriatum

Substanzen

LevodopaEstrogensAntiparkinson Agents

Autor:innen und Institutionen

  • Department of Anatomy, University of Otago, Dunedin, New Zealand.

ORCID-Profile: Lily M Bentall, Louise C Parr-Brownlie

Förderung

  • Neurological Foundation of New Zealand

Zitieren

APA

Bentall, L. M., & Parr-Brownlie, L. C. (2025). Sexual Dimorphism in Levodopa‐Induced Dyskinesia Following Parkinson's Disease: Uncharted Territory. European Journal of Neuroscience. https://doi.org/10.1111/ejn.70144

Vancouver

Bentall LM, Parr-Brownlie LC. Sexual Dimorphism in Levodopa‐Induced Dyskinesia Following Parkinson's Disease: Uncharted Territory. European Journal of Neuroscience. 2025. doi:10.1111/ejn.70144

BibTeX
@article{Bentall2025,
  author = {Bentall, Lily M and Parr-Brownlie, Louise C},
  title = {Sexual Dimorphism in Levodopa‐Induced Dyskinesia Following Parkinson's Disease: Uncharted Territory},
  journal = {European Journal of Neuroscience},
  year = {2025},
  doi = {10.1111/ejn.70144}
}
Kostenlos starten →